Should I Buy CRIS? CRIS 2026 Analysis

Should You Buy Curis Inc (CRIS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.030

1 Day change

13.07%

52 Week Range

3.410

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: trend/positioning is still bearish (SMA_200 > SMA_20 > SMA_5) and price ($0.89) is below the pivot ($0.903), suggesting weak control by buyers.
No Intellectia buy signals (AI Stock Picker and SwingMax both show no signal), so there’s no strong tactical edge for an impatient entry.
Statistical pattern outlook provided is negative (higher odds of drifting lower over 1W/1M), which is unfavorable for buying immediately.
Fundamentals show small revenue growth but worsening losses and margin compression in the latest reported quarter (2025/Q3), which weakens the near-term bull case.

Technical Analysis

Trend: Bearish overall (SMA_200 > SMA_20 > SMA_5), indicating the stock is still in a downtrend despite a small bounce.
Momentum: MACD histogram is positive and expanding (0.00637), hinting at a short-term rebound attempt, but it’s not yet strong enough to reverse the broader bearish MA structure.
RSI: RSI_6 = 43.17 (neutral/soft), not signaling an oversold “must-buy” condition.
Levels: Pivot 0.903; current 0.89 is below pivot (bearish). Support at S1 0.843 then S2 0.806. Resistance at R1 0.963 then R2 1.00.
Price action context: Up modestly today (+2.18%), but still trading under key reference (pivot) with overhead resistance close by.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- MACD turning positive suggests a possible short-term bounce attempt.
- Revenue grew YoY in the latest quarter (2025/Q3 +8.36%).
- No notable recent hedge fund or insider accumulation/distribution trends (both reported as neutral), reducing the risk of a clear “smart money” exit signal.

Neutral/Negative Catalysts

- Primary trend remains bearish (moving averages stacked bearishly), increasing the odds that rallies fade.
- Pattern-based forward odds provided skew negative: ~50% chance of -0.49% next day, -1.35% next week, -4.71% next month.
- Latest quarter showed deterioration in profitability and margin (net loss widened YoY; gross margin down sharply), which can pressure sentiment in micro-cap biotech.
- No news catalysts in the last week to drive a strong rerating.
- No recent congress trading data available (no influential buying signal).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $3.176M, up 8.36% YoY (growth, but modest in absolute dollars).
Net income: -$7.729M, down -23.41% YoY (larger loss vs prior year).
EPS: -0.49, down -71.18% YoY (meaningfully worse).
Gross margin: 71.66, down -31.34% YoY (material compression, a negative quality signal).
Overall: growth exists, but profitability/margins are trending the wrong way in the most recent quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

The provided analyst notes appear to reference Caris Life Sciences, not Curis Inc (CRIS), so they are not reliable for assessing CRIS sentiment.
With no clearly applicable CRIS analyst rating/target changes in the dataset, there’s no supportive Wall Street-driven catalyst indicated here.
Wall Street pro/con view (from available data only): Pros—none clearly attributable to CRIS in this feed; Cons—lack of fresh supportive coverage/targets reduces the chance of near-term rerating.

2 Analyst Rating

Wall Street analysts forecast CRIS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRIS is 11 USD with a low forecast of 5 USD and a high forecast of 17 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.911

Low

Averages

High

Current: 0.911

Low

Averages

High

Evercore ISI

Outperform

downgrade

$40 -> $38

AI Analysis

2026-01-05

Reason

Evercore ISI

Price Target

$40 -> $38

AI Analysis

2026-01-05

downgrade

Outperform

Reason

Evercore ISI lowered the firm's price target on Caris Life Sciences to $38 from $40 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

Canaccord

Kyle Mikson

Hold

maintain

$28 -> $30

2025-12-22

Reason

Canaccord

Kyle Mikson

Price Target

$28 -> $30

2025-12-22

maintain

Hold

Reason

Canaccord analyst Kyle Mikson raised the firm's price target on Caris Life Sciences to $30 from $28 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. They beleve Caris Life Sciences could be attractive with continued momentum or a material share price pullback.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRIS

Unlock Now

CRIS Should I Buy

CRIS Should I Buy

Should You Buy Curis Inc (CRIS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch